Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q1 2025 value amounting to 188.49%.

  • Centessa Pharmaceuticals' EBITDA Margin changed N/A to 188.49% in Q1 2025 from the same period last year, while for Sep 2025 it was 1614.62%, marking a year-over-year decrease of 78383200.0%. This contributed to the annual value of 2161.02% for FY2023, which is N/A changed from last year.
  • Per Centessa Pharmaceuticals' latest filing, its EBITDA Margin stood at 188.49% for Q1 2025.
  • Centessa Pharmaceuticals' 5-year EBITDA Margin high stood at 3979.73% for Q2 2022, and its period low was 188.49% during Q1 2025.
  • Moreover, its 3-year median value for EBITDA Margin was 1950.75% (2022), whereas its average is 2029.36%.
  • The largest annual percentage gain for Centessa Pharmaceuticals' EBITDA Margin in the last 5 years was -5451800bps (2023), contrasted with its biggest fall of -30270400bps (2023).
  • Over the past 3 years, Centessa Pharmaceuticals' EBITDA Margin (Quarter) stood at 1950.75% in 2022, then fell by -28bps to 1405.56% in 2023, then plummeted by -113bps to 188.49% in 2025.
  • Its EBITDA Margin was 188.49% in Q1 2025, compared to 1405.56% in Q4 2023 and 1527.55% in Q3 2023.